My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
March 2016
PRACTICE MANAGEMENT
Changes to CMS Sepsis Quality Measure Based on IDSA Input
In response to a discussion among IDSA members via the Emerging Infections Network (EIN), the following update is provided by Ron Nahass, MD, FIDSA, chair of the IDSA Quality Improvement Committee on the issue of the Sepsis Measure within the Centers for Medicare and Medicaid Service’s (CMS) Inpatient Quality Reporting Program.  
 
In June 2015, IDSA became aware of changes in the measure specification for the Sepsis Bundle Project performance measure (SEP-1) implemented in the National Hospital Inpatient Quality Reporting Program. Specifically, the SEP-1 measure specifications included a recommended list of broad-spectrum antibiotics for monotherapy, (see Appendix C, Table 5.0 of the Specifications Manual for National Hospital Inpatient Quality Measures, Version 5.0b (.zip) (Note: this link opens a zip file containing several reference documents related to the Sepsis Measure). The list included several antibiotics that were deemed by IDSA to be inappropriate and excluded several antibiotics that would be appropriate for many septic cases where a source of infection is suspected or known.  Based upon the specifications provided by CMS, hospitals would be penalized for appropriately treating patients with narrow-spectrum antibiotics.
 
In August 2015, IDSA led advocacy efforts to engage CMS, as documented in a formal joint letter, which recommended changes to CMS on how to best correct the issues with the SEP-1 measure specifications.  As a result of the comments provided by IDSA and other stakeholders, CMS instructed the Joint Commission to revise the specifications. The changes requested by IDSA and others are reflected in Specifications Manual for National Hospital Inpatient Quality Measures v.5.1 (.zip) (Note: several documents are contained within this zip file), released in December 2015, removing Augmentin, which is only available in oral formulation, and Tequin, which was removed from the market due to safety reasons.  
 
IDSA welcomes further member input on the issues with SEP-1 measure. Please feel free to contact Andres Rodriguez, arodriguez@idsociety.org or Thomas Kim, tkim@idsociety.org, for more information regarding IDSA’s work with SEP-1.   
 
Public Comment Period Open for Quality Measure: 72-hour Review of Sepsis Therapy 
 
To encourage the appropriate use of broad-spectrum antibiotics, a joint work group of IDSA and the Society for Healthcare Epidemiology of America (SHEA) developed a corollary quality measure concept to track 72-hour review of all sepsis cases. This measure would require providers to review all sepsis cases at or before 72-hours of administration of broad-spectrum antibiotics for possible de-escalation according to available blood culture, diagnostic, and susceptibility data. 
 
IDSA has opened a public comment period and welcomes public review of the 72-hour Review of Sepsis measure concept. The public comment period closes on March 22, 2016
 
Please visit the following link to submit your comment. https://www.surveymonkey.com/r/XMZWKBD
 


< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
Infections Associated with Heater-Cooler Devices
HCV Guidance Website Updated to Reflect Latest Drug Developments
HIVMA Joins Leading Health and Healthcare Organizations in Choosing Wisely® Campaign
PRACTICE MANAGEMENT
What’s Facing ID Specialists in the Health Care Payment Reform Landscape?
Deadline Extended to Avoid 2017 Medicare EHR Incentive Program Payment Penalties
Changes to CMS Sepsis Quality Measure Based on IDSA Input
Hepatitis C Treatment Access Resources for Providers
IDSA, HIVMA Join in Development of Core Quality Measures
POLICY AND ADVOCACY
Take 3 Minutes to Support Legislative Proposal to Appropriately Value ID Services
IDSA Supports Senate Committee Effort to Address CRE Outbreaks from Duodenoscopes
IDSA Comments on NSABB Draft Recommendations on Gain-of-Function Research
GLOBAL ID
Science Speaks
EDUCATION AND RESOURCES
ABIM Updates
Free Hepatitis C Module and Other MOC Resources
YOU AND YOUR COLLEAGUES
Apply Now for IDSA Fellow Advancement
Nominate Your Colleague for an IDSA or HIVMA Award
Member Report
FROM THE PRESIDENT
Zika: Working Together as Specialists and a Society to End an Outbreak
TOP STORIES
What Comes to Mind When You Hear of New Orleans in October? Think IDWeek!
Call for Committee Volunteers!
President’s Budget Request for FY 2017 is Out: What it Holds for ID and HIV
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.